In light of a recent jury verdict awarding $9 billion in damages to a man who developed cancer because of his diabetes treatment with Actos just what are the allegations that are contained in an Actos bladder cancer lawsuit?
Court records show that there are over 3,000 Actos bladder cancer lawsuits in state and federal courts across the country and they have a common theme:
The victims claim that their use of Actos to treat diabetes caused them to develop bladder cancer and that the manufacturer of the medication, Asian drug-making giant Takeda Pharmaceuticals, and its American partner, Eli Lilly, failed to warn patients of this danger.
One plaintiff’s claims are similar to the others in alleging he “was injured as a result of his use of Actos, and therefore seeks damages for pain and suffering, ascertainable economic losses, attorneys’ fees, reimbursement of cost of Actos, reimbursement for all past, present and future health and medical care costs related to Actos.”
The victim also is seeking compensation for his wife who, according to the lawsuit “was deprived of the care, consideration, compassion, consortium and concern” from the victim.
The victim claims that “as a result of the defective nature of Actos” he and other patients who were prescribed the drug suffer from bladder cancer, for which he was hospitalized.
“Defendants concealed and continue to conceal their knowledge of Actos’ unreasonably dangerous risk from Plaintiff, his physicians, other consumers, and the medical community,” according to the lawsuit.
“Specifically, Defendants failed to adequately inform consumers and the prescribing medical community about the risk of bladder cancer associated with more than twelve months of Actos ingestion.”
Also named as a defendant in this and other lawsuits in the multi-district litigation is Eli Lilly, which the plaintiff said collaborated with Takeda “to promote and market Actos.”
The victim also claims that “Defendants have yet to adequately inform consumers and the prescribing medical community about the risks of bladder cancer with the use of Actos for more than 12 months.
The number of Actos bladder cancer lawsuits surged shortly after the U.S. Food & Drug Administration issued a warning in June 2011 that long-term use of the drug significantly increased the risk of patients developing bladder cancer.
The most recent trial in which a $9 million Louisiana jury verdict was returned in favor a New York man who developed bladder cancer was the first from thousands now consolidated before a federal judge in Louisiana.
There is also another Actos bladder cancer trial underway in Nevada, where an attorney for two Las Vegas women who developed bladder cancer after being treated for diabetes with Actos also are seeking over a billion dollars in damages.
Among the damages being sought by victims of Actos-caused bladder cancer are medical expenses, lost wages, pain and suffering and other costs, according to the court files.